Headlines about CASI Pharmaceuticals (NASDAQ:CASI) have been trending somewhat negative this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. CASI Pharmaceuticals earned a coverage optimism score of -0.02 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 45.9909128558608 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
CASI has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and set a $4.50 target price on shares of CASI Pharmaceuticals in a research note on Monday, January 29th. Maxim Group set a $4.00 target price on shares of CASI Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, November 14th. Finally, BidaskClub downgraded shares of CASI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 14th.
Shares of CASI Pharmaceuticals (CASI) opened at $3.73 on Tuesday. CASI Pharmaceuticals has a 52 week low of $0.91 and a 52 week high of $4.84. The firm has a market cap of $269.13, a price-to-earnings ratio of -24.87 and a beta of 0.71.
COPYRIGHT VIOLATION NOTICE: “CASI Pharmaceuticals (CASI) Receives Coverage Optimism Score of -0.02” was published by Ticker Report and is the property of of Ticker Report. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/3226146/casi-pharmaceuticals-casi-receives-coverage-optimism-score-of-0-02.html.
CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.